Clinical Trial Detail

NCT ID NCT03600155
Title Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Nivolumab

Ipilimumab

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.